NZ554723A - Antisense oligonucleotides against CCR3 chemokine receptor - Google Patents

Antisense oligonucleotides against CCR3 chemokine receptor

Info

Publication number
NZ554723A
NZ554723A NZ554723A NZ55472305A NZ554723A NZ 554723 A NZ554723 A NZ 554723A NZ 554723 A NZ554723 A NZ 554723A NZ 55472305 A NZ55472305 A NZ 55472305A NZ 554723 A NZ554723 A NZ 554723A
Authority
NZ
New Zealand
Prior art keywords
oligonucleotide
seq
pharmaceutical composition
antisense oligonucleotide
antisense
Prior art date
Application number
NZ554723A
Other languages
English (en)
Inventor
Khalid Zemzoumi
Paolo Renzi
Original Assignee
Topigen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topigen Pharmaceuticals Inc filed Critical Topigen Pharmaceuticals Inc
Publication of NZ554723A publication Critical patent/NZ554723A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/331—Universal or degenerate base

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ554723A 2004-10-29 2005-10-27 Antisense oligonucleotides against CCR3 chemokine receptor NZ554723A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62320604P 2004-10-29 2004-10-29
PCT/CA2005/001656 WO2006045202A1 (en) 2004-10-29 2005-10-27 Antisense oligonucleotides for treating allergy and neoplastic cell proliferation

Publications (1)

Publication Number Publication Date
NZ554723A true NZ554723A (en) 2009-12-24

Family

ID=36226992

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ554723A NZ554723A (en) 2004-10-29 2005-10-27 Antisense oligonucleotides against CCR3 chemokine receptor

Country Status (12)

Country Link
US (2) US8119790B2 (enExample)
EP (1) EP1812075B1 (enExample)
JP (1) JP5314283B2 (enExample)
CN (1) CN101087623B (enExample)
AU (1) AU2005299218B2 (enExample)
BR (1) BRPI0517387A8 (enExample)
CA (1) CA2584457C (enExample)
ES (1) ES2450929T3 (enExample)
MX (1) MX2007005083A (enExample)
NZ (1) NZ554723A (enExample)
RU (1) RU2416412C2 (enExample)
WO (1) WO2006045202A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285961A4 (en) 2008-05-15 2012-10-17 Topigen Pharmaceuticals Inc OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION
ES2625689T3 (es) 2010-04-29 2017-07-20 Ionis Pharmaceuticals, Inc. Modulación de la expresión de transtiretina
JP2014511181A (ja) * 2011-02-24 2014-05-15 ファーマキシス リミテッド キメラ骨格および２−アミノ−２’−デオキシアデノシンを有するオリゴヌクレオチド阻害剤
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2015066262A1 (en) * 2013-11-04 2015-05-07 Trustees Of Dartmouth College Methods for preventing toxicity of adoptive cell therapy
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337530A (en) 1965-09-20 1967-08-22 Upjohn Co Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
JPH0825869B2 (ja) 1987-02-09 1996-03-13 株式会社ビタミン研究所 抗腫瘍剤包埋リポソ−ム製剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5872242A (en) 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US6806061B1 (en) * 1995-01-19 2004-10-19 Children's Medical Center Corporation G protein-coupled receptor gene and methods of use therefor
US5874211A (en) 1995-04-13 1999-02-23 Incyte Pharmaceuticals, Inc. Chemokine expressed in eosinophils
FR2734147B1 (fr) 1995-05-19 1997-10-10 Klein Jean Michel Dispositif d'osteosynthese implantable
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US6025339A (en) 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
FR2742156A1 (fr) 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997023244A1 (en) 1995-12-22 1997-07-03 Smithkline Beecham Corporation Use of antisene oligodeoxynucleotides to produce truncated proteins
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
EP1012190A4 (en) 1996-04-26 2004-04-28 Merck & Co Inc Eotaxin receptor from eosinophils
JP2000510690A (ja) 1996-04-26 2000-08-22 インサイト・ファーマスーティカルズ・インコーポレイテッド 哺乳類混合リンパ球受容体、ケモカイン受容体（ｍｍｌｒ―ｃｃｒ）
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
EP1019065A4 (en) 1997-09-17 2002-02-20 Univ East Carolina NUCLEIC ACIDS HYBRIDIZING TO MULTIPLE TARGETS, THEIR PREPARATION, COMPOSITIONS, FORMULATION, KITS AND APPLICATIONS
CA2235420A1 (en) * 1998-06-17 1999-12-17 Paolo Renzi Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation
ATE346918T1 (de) 1998-06-19 2006-12-15 Univ Mcgill Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
HK1042706A1 (zh) 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
US6175004B1 (en) 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
AU4031700A (en) 1999-04-06 2000-11-02 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation,allergy(ies) and surfactant depletion
CA2419563C (en) 2000-09-06 2018-03-20 Mcgill University Chimeric antisense of arabinofuranose analogue and deoxyribose nucleotides
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
PT1406667E (pt) 2001-07-06 2008-05-23 Topigen Pharmaceuticals Inc Métodos para aumentar a eficácia in vivo de oligonucleótidos e a inibição da inflamação em mamíferos
JP2005508634A (ja) 2001-10-29 2005-04-07 マクギル・ユニヴァーシティ 非環式リンカー含有オリゴヌクレオチド及びその用途
DK1470144T3 (da) 2002-02-01 2009-04-06 Univ Mcgill Oligonukleotider omfattende alternerende segmenter og anvendelser deraf

Also Published As

Publication number Publication date
CN101087623A (zh) 2007-12-12
AU2005299218B2 (en) 2012-04-12
EP1812075A4 (en) 2010-04-07
AU2005299218A2 (en) 2008-10-30
RU2007119777A (ru) 2008-12-10
US8119790B2 (en) 2012-02-21
BRPI0517387A (pt) 2008-10-07
AU2005299218A1 (en) 2006-05-04
ES2450929T3 (es) 2014-03-25
MX2007005083A (es) 2007-10-03
CA2584457C (en) 2012-10-23
WO2006045202A1 (en) 2006-05-04
EP1812075B1 (en) 2013-12-11
US8202851B2 (en) 2012-06-19
CA2584457A1 (en) 2006-05-04
US20090215861A1 (en) 2009-08-27
EP1812075A1 (en) 2007-08-01
RU2416412C2 (ru) 2011-04-20
BRPI0517387A8 (pt) 2017-07-11
JP2008517953A (ja) 2008-05-29
JP5314283B2 (ja) 2013-10-16
CN101087623B (zh) 2012-09-26
US20120065249A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
US8470999B2 (en) Oligonucleotides for treating inflammation and neoplastic cell proliferation
AU2004275903B2 (en) Oligonucleotide compositions and methods for treating disease including inflammatory conditions
JP2016521556A (ja) Ｆｏｘｐ３発現を調節するための組成物及び方法
US8202851B2 (en) Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
EP3033114A1 (en) Heterochromatin forming non-coding rnas
WO2019040590A1 (en) MODULATION OF THE EXPRESSION OF SOLUBLE FAS
JP2022513111A (ja) Ａｎｇｐｔｌ８を阻害するための新規のｒｎａ組成物および方法
AU2007252192B2 (en) Oligonucleotides affecting expression of phosphodiesterases
JP7241098B2 (ja) 線維症治療剤
CA2827782A1 (en) Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine

Legal Events

Date Code Title Description
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: THE APPLICANT (71) HAS BEEN CORRECTED

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2016 BY WRAYS

Effective date: 20150812

ASS Change of ownership

Owner name: PHARMAXIS LTD, AU

Effective date: 20160602

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2017 BY WRAYS

Effective date: 20160928

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 OCT 2018 BY WRAYS

Effective date: 20171002

LAPS Patent lapsed